In November 2020 OssDsign completed the acquisition of the privately held Scottish bone graft specialist company Sirakoss Ltd, expanding into the spinal bone graft market. The acquisition broadens OssDsign’s product portfolio with OssDsign Catalyst an FDA 510(k) cleared next-generation nanosynthetic bone graft substitute that stimulates the formation of healthy bone tissue.